Clinical Trial Update: Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating azacitidine with or without entinostat in patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid le…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Azacitidine (Vidaza) (azacitidine)
• Entinostat (MS-275) (entinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Status: COMPLETED | Results posted: 2014-11-25